Insomnia and Sleep Disorders in the UK
Chronic insomnia affects approximately one in three UK adults, with one in ten experiencing clinically significant insomnia disorder. It is associated with substantially increased risks of depression, anxiety, cardiovascular disease, type 2 diabetes, and immune dysfunction. The economic burden of sleep disorders in the UK has been estimated at over 30 billion pounds annually.
NICE-recommended first-line treatment for chronic insomnia is cognitive behavioural therapy for insomnia (CBT-I). While effective, CBT-I has limitations: it requires sustained patient engagement, is not universally available through NHS pathways, and shows variable efficacy in insomnia comorbid with pain, trauma, or anxiety disorders. Pharmacological options including z-drugs, benzodiazepines, and low-dose antidepressants are effective for short-term use but carry significant dependency and tolerance risks with long-term application.
How Cannabinoids Influence Sleep
Cannabis has been used for sleep induction for centuries, and the neurobiological mechanisms are now reasonably well characterised. The endocannabinoid system is deeply involved in the regulation of sleep-wake cycles, with endocannabinoids modulating adenosine signalling (the primary homeostatic driver of sleep pressure), activity in the hypothalamic sleep-wake switch, and circadian rhythm circuits.
THC, as a CB1 receptor agonist, produces dose-dependent effects on sleep architecture: it typically reduces sleep onset latency, decreases wakefulness after sleep onset, and increases slow-wave sleep (the deepest, most restorative stage). At therapeutic doses, THC suppresses REM sleep. CBD, through multiple mechanisms including 5-HT1A agonism, GABA-A receptor modulation, and cortisol regulation, has been shown to reduce anxiety and improve sleep quality, particularly in patients whose insomnia has an anxious component.
Evidence for Cannabinoids in Insomnia
- A 2019 study in The Permanente Journal found that 67% of patients reporting sleep as a primary concern experienced improved sleep scores within the first month of CBD treatment, with most retaining improvement at three months.
- Data from the UK Medical Cannabis Registry demonstrates significant improvements in Pittsburgh Sleep Quality Index (PSQI) scores in patients prescribed cannabis-based medicines for conditions including chronic pain, anxiety, and PTSD.
- A 2021 Australian study of 23,000 patients found that medical cannabis users reported significantly better sleep quality and reduced daytime fatigue compared to pre-treatment baseline.
Practical Considerations for Prescribing
The optimal approach to prescribing medical cannabis for insomnia depends heavily on the underlying cause. For insomnia driven by pain, a balanced THC:CBD formulation taken in the evening is preferred. For anxiety-related insomnia, a CBD-dominant daytime dose combined with a THC-containing evening dose may be recommended. For PTSD-related insomnia with nightmares, a moderate-THC evening product is most often prescribed.
As with all medical cannabis prescribing in the UK, the starting dose is kept low and increased gradually under specialist supervision. Patients driving motor vehicles must understand that THC-containing products can affect driving performance; your specialist will advise on the appropriate interval between dosing and driving.
The UK Prescribing Pathway for Sleep Disorders
To access medical cannabis for insomnia in the UK, a specialist will typically require evidence that CBT-I has been attempted and that at least one pharmacological sleep aid has been trialled without adequate benefit or was poorly tolerated. All Cannamedical Britannia products are EU-GMP certified, ensuring pharmaceutical-grade quality with full batch documentation.